Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49062 | 0.76 | CA2 (0.50) | GRIK1GRIK2FOLH1 | |
| SCHEMBL4429920 | 0.76 | FOLH1 (0.33) | FOLH1 | |
| SCHEMBL10658816 | 0.74 | FOLH1 (0.39) | GRIK1GRIK2FOLH1 | |
| SCHEMBL891727 | 0.73 | GRIK1 (0.64) | GRIK1GRIK2CPA1TBXAS1CYP2C19 | |
| SCHEMBL4333917 | 0.73 | FOLH1 (0.41) | GRIK1GRIK2FOLH1 | |
| SCHEMBL2137236 | 0.72 | GRIK1 (0.53) | GRIK1GRIK2CPA1TBXAS1CYP2C19 | |
| SCHEMBL8031351 | 0.72 | GRIK1 (0.53) | GRIK1GRIK2CPA1TBXAS1CYP2C19 | |
| SCHEMBL6050002 | 0.71 | GRIK1 (0.75) | GRIK1GRIK2CPA1TBXAS1CYP2C19 | |
| SCHEMBL13258636 | 0.71 | GRIK1 (0.57) | GRIK1GRIK2CPA1TBXAS1CYP2C19 | |
| 4-En-Metabolite SCHEMBL9111371 | 0.71 | CHRM1 (0.62) | GRIK1GRIK2CPA1TBXAS1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008132541-A2 | CONJUGATES OF 2-FLUORO-2-DEOXY-GLUCOSE AND THEIR USES AS ANTI CANCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-11-06 | — | — | WO | disclosed |